Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
22 Mar 24
NT 10-Q
Notice of late quarterly filing
18 Mar 24
S-8
Registration of securities for employees
5 Jan 24
S-8
Registration of securities for employees
5 Jan 24
8-K
Entry into a Material Definitive Agreement
5 Jan 24
8-A12G
Registration of securities
5 Jan 24
8-K
Completion of Acquisition or Disposition of Assets
29 Dec 23
10-Q
2024 Q1
Quarterly report
15 Dec 23
8-K
Regulation FD Disclosure
13 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
7 Dec 23
10-K/A
2023 FY
Annual report (amended)
28 Nov 23
8-K
Entry into a Material Definitive Agreement
2 Nov 23
DEF 14A
Definitive proxy
30 Oct 23
10-K
2023 FY
Annual report
30 Oct 23
PRE 14A
Preliminary proxy
19 Oct 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
8-K
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
5 Oct 23
8-K
Entry into a Material Definitive Agreement
18 Aug 23
8-K
Entry into a Material Definitive Agreement
7 Jul 23
8-K
Regulation FD Disclosure
28 Jun 23
10-Q
2023 Q3
Quarterly report
14 Jun 23
8-K
Entry into a Material Definitive Agreement
4 Apr 23
10-Q
2023 Q2
Quarterly report
17 Mar 23
8-K
Submission of Matters to a Vote of Security Holders
13 Jan 23
8-K
Departure of Directors or Certain Officers
6 Jan 23
8-K
Entry into a Material Definitive Agreement
3 Jan 23
10-Q
2023 Q1
Quarterly report
14 Dec 22
DEF 14A
Definitive proxy
29 Nov 22
8-K
Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development
25 Nov 22
8-K
Other Events
23 Nov 22
8-K
Entry into a Material Definitive Agreement
23 Nov 22
PRE 14A
Preliminary proxy
18 Nov 22
8-K
Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team
4 Nov 22
8-K
Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device
1 Nov 22
10-K
2022 FY
Annual report
31 Oct 22
8-K
Entry into a Material Definitive Agreement
3 Oct 22
8-K
Odyssey Health, Inc. Makes Statement Regarding its Concussion Drug Development Program
30 Sep 22
8-K
Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug
30 Sep 22
8-K
Other Events
15 Sep 22
8-K
Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial
18 Aug 22
Latest ownership filings
SC 13D
ORAGENICS INC
12 Feb 24
4
Gregory W Gironda
18 Jan 24
4
Erik C. Emerson
18 Jan 24
4
JOHN P GANDOLFO
16 Jan 24
4
Erik C. Emerson
2 Jan 24
4
CHRISTINE FARRELL
2 Jan 24
4
Gregory W Gironda
2 Jan 24
4
Jerome H Casey
2 Jan 24
4
J MICHAEL REDMOND
2 Jan 24
4
RICKY RICHARDSON
2 Jan 24
SC 13G
Lutz Jonathan D
28 Jul 23
4
RICKY RICHARDSON
13 Jan 23
4
J MICHAEL REDMOND
13 Jan 23
4
JOHN P GANDOLFO
13 Jan 23
4
CHRISTINE FARRELL
13 Jan 23
4
Jerome H Casey
13 Jan 23
4
Gregory W Gironda
23 Nov 22
3
Gregory W Gironda
23 Nov 22
4
Erik C. Emerson
23 Nov 22
3
Erik C. Emerson
23 Nov 22
4
JACOB PH.D VANLANDINGHAM
19 Oct 22
4
CHRISTINE FARRELL
19 Oct 22
4
J MICHAEL REDMOND
15 Sep 22
4
JACOB PH.D VANLANDINGHAM
14 Jun 22
4
JACOB PH.D VANLANDINGHAM
8 Jun 22
4
RICKY RICHARDSON
8 Jun 22
4
J MICHAEL REDMOND
8 Jun 22
4
JOHN P GANDOLFO
8 Jun 22
4
CHRISTINE FARRELL
8 Jun 22
4
Jeffrey X Conroy
8 Jun 22
4
Jerome H Casey
8 Jun 22
4
JOHN P GANDOLFO
16 Sep 21
4
Jeffrey X Conroy
16 Sep 21
4
Jerome H Casey
16 Sep 21
3
RICKY RICHARDSON
19 May 21
4
JACOB PH.D VANLANDINGHAM
9 Apr 21
4
J MICHAEL REDMOND
1 Mar 21
4
CHRISTINE FARRELL
1 Mar 21
3
CHRISTINE FARRELL
1 Dec 20
3
J MICHAEL REDMOND
11 Dec 19